Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Med Imaging Radiat Oncol ; 67(8): 895-902, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38062853

ABSTRACT

Imaging and image processing is the fundamental pillar of interventional oncology in which diagnostic, procedure planning, treatment and follow-up are sustained. Knowing all the possibilities that the different image modalities can offer is capital to select the most appropriate and accurate guidance for interventional procedures. Despite there is a wide variability in physicians preferences and availability of the different image modalities to guide interventional procedures, it is important to recognize the advantages and limitations for each of them. In this review, we aim to provide an overview of the most frequently used image guidance modalities for interventional procedures and its typical and future applications including angiography, computed tomography (CT) and spectral CT, magnetic resonance imaging, Ultrasound and the use of hybrid systems. Finally, we resume the possible role of artificial intelligence related to image in patient selection, treatment and follow-up.


Subject(s)
Artificial Intelligence , Tomography, X-Ray Computed , Humans , Tomography, X-Ray Computed/methods , Ultrasonography , Image Processing, Computer-Assisted , Medical Oncology
2.
Clin Nucl Med ; 44(8): e465-e471, 2019 08.
Article in English | MEDLINE | ID: mdl-31274625

ABSTRACT

Bone metastasis (BM) in differentiated thyroid cancer (DTC) is the second most common site of metastasis after lung. Bone metastases are associated with worse prognosis in DTC. In this study, we examined risk factors for overall survival in patients with BM and for the first time explore the pattern of genomic alterations in DTC BM. PATIENTS AND METHODS: A Health Insurance Portability and Accountability Act (HIPAA) compliant, institutional review board-approved retrospective evaluation of the medical record was performed for all patients treated at a single institution for thyroid cancer over a 16-year period. Seventy-four patients met inclusion criteria. Multiple prognostic factors including age, sex, genes, radioactive iodine, and radiation or kinase inhibitor therapies were analyzed. Univariate and multivariate analyses were performed. RESULTS: Treatment with external beam radiation was found to significantly increase survival (P = 0.03). The 5-year survival rate was 59% and median survival was 92 months. Patients who developed bone metastasis earlier tend to live longer (P = 0.06). The presence of TERT and BRAF mutations did not significantly worsen the prognosis (P = 0.10). CONCLUSION: Patients with DTC can benefit from early treatment with external beam radiation therapy, especially those who develop bone metastasis within 3 years of primary TC diagnosis. Kinase inhibitor treatment tended to prolong survival but not in a statistically significant manner. Sex, age, and TERT or BRAF genetic mutations did not significantly affect the prognosis.


Subject(s)
Bone Neoplasms/genetics , Bone Neoplasms/secondary , Genomics , Tertiary Healthcare , Thyroid Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Bone Neoplasms/diagnosis , Female , Humans , Male , Middle Aged , Mutation , Prognosis , Proto-Oncogene Proteins B-raf/genetics , Retrospective Studies , Risk Factors , Survival Rate
3.
Clin Nucl Med ; 44(7): 544-549, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31107749

ABSTRACT

PURPOSE: Brain metastases (BMs) in patients with differentiated thyroid cancer (DTC) are rare but associated with poor prognosis. We examined risk factors for overall survival (OS) in this population and explored the pattern of genomic alterations. METHODS: Single-institution, retrospective review of all patients with DTC from January 2000 to November 2016 identified 79 patients for analysis. Multiple prognostic factors, including age, gender, distal metastasis (DM), diagnosis time, DM sites, BM diagnosis time, BM number and size, genomic sequencing data, craniectomy, external beam radiation therapy, and kinase inhibitor therapies, were evaluated. Univariate and multivariate analyses were performed. RESULTS: Median survival after BM was 18 months. One- and 3-year survival rates were 63% and 33%, respectively. Univariate analysis identified 4 covariates correlated with prolonged survival: time between DTC diagnosis and BM for less than 3 years (P = 0.01), time from initial DM diagnosis to BM for 22 months or less (P = 0.03), 3 BM sites or fewer (P = 0.002), and craniectomy (P = 0.05). Multivariate model revealed 3 variables associated with OS: DTC diagnosis to BM time of less than 3 years (P = 0.04), craniectomy (P = 0.06), and patients with fewer than 3 BM sites (P = 0.06). The majority of patients with BM had a telomerase reverse transcriptase promoter mutation, However, mutational status was not an independent predictor of survival. CONCLUSIONS: For BM from DTC, time interval between DTC diagnosis and BM, number of BM sites, and craniectomy were independently associated with OS. Further studies are needed to define the role of genomic mutations in advanced cancer.


Subject(s)
Adenocarcinoma/pathology , Brain Neoplasms/secondary , Oncogenes , Thyroid Neoplasms/pathology , Adenocarcinoma/epidemiology , Adenocarcinoma/genetics , Adult , Aged , Brain Neoplasms/epidemiology , Brain Neoplasms/genetics , Female , Humans , Male , Middle Aged , Survival Rate , Tertiary Healthcare/statistics & numerical data , Thyroid Neoplasms/epidemiology , Thyroid Neoplasms/genetics
4.
Cancer Epidemiol Biomarkers Prev ; 28(3): 478-485, 2019 03.
Article in English | MEDLINE | ID: mdl-30733308

ABSTRACT

BACKGROUND: The Bedford-Stuyvesant (BS) and Bushwick (BW) communities of central Brooklyn, New York, are located within the 50-mile core radius of Memorial Sloan Kettering's main catchment area. Cancer is the second leading cause of death among the predominantly African American and Hispanic neighborhoods, with BS and BW having higher prostate cancer and colorectal mortality rates than New York City as a whole. There is significant opportunity to design cancer interventions that leverage the accessibility and acceptability of mobile health (mHealth) tools among the BS and BW communities. METHODS: The Cancer Health Impact Program (CHIP) is a collaborative that was formed for this purpose. Through CHIP, we used a tablet-based, Health Information National Trends (HINTS)-based multimodality survey to collect and analyze social and demographic patterns of prostate cancer and colorectal cancer screening, as well as mHealth access, among BS and BW residents. RESULTS: Among 783 participants, 77% reported having a smartphone, 40% reported access to a mobile health application, 17% reported blood stool kit testing, and 26% of men reported PSA test screening. Multivariable logistic regression models results demonstrated that participants who reported owning smartphones, but were unsure whether they had access to a health app, were also significantly more likely to report blood stool kit testing compared with participants without smartphones. In fully adjusted models, access to a health app was not significantly associated with PSA testing. Non-Hispanic white participants were 86% less likely to report blood stool kit testing when compared with non-Hispanic black participants [OR = 0.15; 95% confidence interval (CI) 0.02-0.49]. Participants with a prior history of cancer were three times more likely to report blood stool kit testing when compared with those without cancer history (OR = 3.18; 95% CI, 1.55-6.63). CONCLUSIONS: For blood stool kit testing, significant differences were observed by race/ethnicity, cancer history, age, and smartphone use; for PSA screening, only age was significant in fully adjusted models. IMPACT: Our results demonstrate that while access to smartphones and mobile health apps may be prevalent among minority communities, other social and demographic characteristics are more likely to influence screening behaviors.


Subject(s)
Colorectal Neoplasms/diagnosis , Early Detection of Cancer/statistics & numerical data , Health Promotion , Health Services Accessibility , Prostatic Neoplasms/diagnosis , Smartphone/statistics & numerical data , Telemedicine/statistics & numerical data , Adolescent , Adult , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/psychology , Demography , Early Detection of Cancer/psychology , Female , Humans , Information Seeking Behavior , Male , Middle Aged , New York City/epidemiology , Prostatic Neoplasms/epidemiology , Prostatic Neoplasms/psychology , Surveys and Questionnaires , Young Adult
6.
J Vasc Interv Radiol ; 29(11): 1519-1526, 2018 11.
Article in English | MEDLINE | ID: mdl-30342802

ABSTRACT

PURPOSE: To identify common gene mutations in patients with neuroendocrine liver metastases (NLM) undergoing transarterial embolization (TAE) and establish relationship between these mutations and response to TAE. MATERIALS AND METHODS: Patients (n = 51; mean age 61 y; 29 men, 22 women) with NLMs who underwent TAE and had available mutation analysis were identified. Mutation status and clinical variables were recorded and evaluated in relation to hepatic progression-free survival (HPFS) (Cox proportional hazards) and time to hepatic progression (TTHP) (competing risk proportional hazards). Subgroup analysis of patients with pancreatic NLM was performed using Fisher exact test to identify correlation between mutation and event (hepatic progression or death) by 6 months. Changes in mutation status over time and across specimens in a subset of patients were recorded. RESULTS: Technical success of TAE was 100%. Common mutations identified were MEN1 (16/51; 31%) and DAXX (13/51; 25%). Median overall survival was 48.7 months. DAXX mutation status (hazard ratio = 6.21; 95% confidence interval [CI], 2.67-14.48; P < .001) and tumor grade (hazard ratio = 3.05; 95% CI, 1.80-5.17; P < .001) were associated with shorter HPFS and TTHP on univariate and multivariate analysis. Median HPFS was 3.6 months (95% CI, 1.7-5.3) for patients with DAXX mutation compared with 8.9 months (95% CI, 6.6-11.4) for patients with DAXX wild-type status. In patients with pancreatic NLMs, DAXX mutation status was associated with hepatic progression or death by 6 months (P = .024). DAXX mutation status was concordant between primary and metastatic sites. CONCLUSIONS: DAXX mutation is common in patients with pancreatic NLMs. DAXX mutation status is associated with shorter HPFS and TTHP after TAE.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Biomarkers, Tumor/genetics , Embolization, Therapeutic/methods , Liver Neoplasms/genetics , Liver Neoplasms/therapy , Mutation , Neuroendocrine Tumors/genetics , Neuroendocrine Tumors/therapy , Nuclear Proteins/genetics , Adult , Aged , Aged, 80 and over , Co-Repressor Proteins , DNA Mutational Analysis , Disease Progression , Embolization, Therapeutic/adverse effects , Embolization, Therapeutic/mortality , Female , Genetic Predisposition to Disease , Humans , Liver Neoplasms/mortality , Liver Neoplasms/secondary , Male , Middle Aged , Molecular Chaperones , Neuroendocrine Tumors/mortality , Neuroendocrine Tumors/secondary , Phenotype , Risk Factors , Time Factors , Treatment Outcome
7.
Cardiovasc Intervent Radiol ; 41(9): 1440-1443, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29728719

ABSTRACT

Fifty-two-year-old female with high-grade undifferentiated pleomorphic left thigh sarcoma and bilateral metastatic soft tissue lesions to the lungs consistent with metastases, presented with recurrent, anemia, and worsening hemoptysis. Cross-sectional imaging demonstrated erosion of a right lower lobe metastatic mass into an adjacent right inferior lower lobe pulmonary vein with formation of a pseudoaneurysm. We report the successful treatment of this pseudoaneurysm via direct image-guided percutaneous access with subsequent coil embolization.


Subject(s)
Aneurysm, False/therapy , Computed Tomography Angiography/methods , Embolization, Therapeutic/methods , Lung Neoplasms/secondary , Pulmonary Veins/diagnostic imaging , Sarcoma/pathology , Aneurysm, False/complications , Female , Humans , Lung Neoplasms/complications , Lung Neoplasms/diagnostic imaging , Middle Aged
8.
PET Clin ; 11(4): 387-402, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27593245

ABSTRACT

Hybrid imaging systems have dramatically improved thoracic oncology patient care over the past 2 decades. PET-MR imaging systems have the potential to further improve imaging of thoracic neoplasms, resulting in diagnostic and therapeutic advantages compared with current MR imaging and PET-computed tomography systems. Increasing soft tissue contrast and lesion sensitivity, improved image registration, reduced radiation exposure, and improved patient convenience are immediate clinical advantages. Multiparametric quantitative imaging capabilities of PET-MR imaging have the potential to improve understanding of the molecular mechanisms of cancer and treatment effects, potentially guiding improvements in diagnosis and therapy.


Subject(s)
Breast Neoplasms/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Magnetic Resonance Imaging/methods , Multimodal Imaging/methods , Positron-Emission Tomography/methods , Breast/diagnostic imaging , Female , Humans , Lung/diagnostic imaging , Male
9.
Clin Imaging ; 39(2): 264-9, 2015.
Article in English | MEDLINE | ID: mdl-25457528

ABSTRACT

We assessed changes in prostate lesions on serial magnetic resonance imaging (MRI) examinations in predicting biopsy results. Fifty-five men undergoing two prostate MRI examinations ≥6 months apart, followed by targeted biopsy, were included. Two radiologists assessed dominant lesions for an increase in size or suspicion score. Progression on MRI had lower sensitivity (23.5%-35.3%) and higher specificity (76.2%-90.5%) than prostate-specific antigen (PSA) velocity (sensitivity 70.6%, specificity 52.4%) for predicting positive biopsy. Highest accuracy was achieved by PSA velocity (63.6%) for positive biopsy, and by MRI (65.5%-72.7%) for Gleason >6 tumor. Findings support lesion progression on MRI serving as a basis for performing subsequent targeted biopsy.


Subject(s)
Adenocarcinoma/pathology , Magnetic Resonance Imaging/methods , Prostate/pathology , Prostatic Neoplasms/pathology , Aged , Aged, 80 and over , Biopsy , Disease Progression , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Prostate-Specific Antigen/analysis , Sensitivity and Specificity
10.
J Nucl Med ; 54(11): 1876-82, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24029655

ABSTRACT

UNLABELLED: Despite their considerable advantages, many circulating biomarkers have well-documented limitations. One prominent shortcoming in oncology is a high frequency of false-positive indications for malignant disease in upfront diagnosis. Because one common cause of false positivism is biomarker production from benign disorders in unrelated host tissues, we hypothesized that probing the sites of biomarker secretion with an imaging tool could be a broadly useful strategy to deconvolute the meaning of foreboding but inconclusive circulating biomarker levels. METHODS: In preparation to address this hypothesis clinically, we developed (89)Zr-5B1, a fully human, antibody-based radiotracer targeting tumor-associated CA19.9 in the preclinical setting. RESULTS: (89)Zr-5B1 localized to multiple tumor models representing diseases with undetectable and supraphysiologic serum CA19.9 levels. Among these, (89)Zr-5B1 detected orthotopic models of pancreatic ductal adenocarcinoma, an elusive cancer for which the serum assay is measured in humans but with limited specificity in part because of the frequency of CA19.9 secretion from benign hepatic pathologies. CONCLUSION: In this report, a general strategy to supplement some of the shortcomings of otherwise highly useful circulating biomarkers with immunoPET is described. To expedite the clinical validation of this model, a human monoclonal antibody to CA19.9 (a highly visible but partially flawed serum biomarker for several cancers) was radiolabeled and evaluated, and the compelling preclinical evidence suggests that the radiotracer may enhance the fidelity of diagnosis and staging of pancreatic ductal adenocarcinoma, a notoriously occult cancer.


Subject(s)
Antigens, Tumor-Associated, Carbohydrate/blood , Biomarkers, Tumor/blood , Neoplasms/blood , Neoplasms/diagnostic imaging , Positron-Emission Tomography/methods , Radioisotopes , Zirconium , Animals , Antibodies, Monoclonal/pharmacokinetics , Cell Line, Tumor , Cell Transformation, Neoplastic , Female , Humans , Mice , Neoplasms/pathology
11.
J Nucl Med ; 54(1): 90-5, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23236019

ABSTRACT

UNLABELLED: A noninvasive technology that indiscriminately detects tumor tissue in the brain could substantially enhance the management of primary or metastatic brain tumors. Although the documented molecular heterogeneity of diseases that initiate or eventually deposit in the brain may preclude identifying a single smoking-gun molecular biomarker, many classes of brain tumors are generally avid for transferrin. Therefore, we reasoned that applying a radiolabeled derivative of transferrin ((89)Zr-labeled transferrin) may be an effective strategy to more thoroughly identify tumor tissue in the brain, regardless of the tumor's genetic background. METHODS: Transferrin was radiolabeled with (89)Zr, and its properties with respect to human models of glioblastoma multiforme were studied in vivo. RESULTS: In this report, we show proof of concept that (89)Zr-labeled transferrin ((89)Zr-transferrin) localizes to genetically diverse models of glioblastoma multiforme in vivo. Moreover, we demonstrate that (89)Zr-transferrin can detect an orthotopic lesion with exceptional contrast. Finally, the tumor-to-brain contrast conferred by (89)Zr-transferrin vastly exceeded that observed with (18)F-FDG, currently the most widely used radiotracer to assess tumor burden in the brain. CONCLUSION: The results from this study suggest that (89)Zr-transferrin could be a broadly applicable tool for identifying and monitoring tumors in the brain, with realistic potential for near-term clinical translation.


Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/pathology , Diagnostic Imaging/methods , Radioisotopes , Transferrin , Tumor Burden , Zirconium , Animals , Cell Line, Tumor , Fluorodeoxyglucose F18 , Glioblastoma/diagnosis , Glioblastoma/pathology , Humans , Male , Mice , Mice, Inbred ICR
12.
Nat Med ; 18(10): 1586-91, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23001181

ABSTRACT

A noninvasive technology that quantitatively measures the activity of oncogenic signaling pathways could have a broad impact on cancer diagnosis and treatment with targeted therapies. Here we describe the development of (89)Zr-desferrioxamine-labeled transferrin ((89)Zr-transferrin), a new positron emission tomography (PET) radiotracer that binds the transferrin receptor 1 (TFRC, CD71) with high avidity. The use of (89)Zr-transferrin produces high-contrast PET images that quantitatively reflect treatment-induced changes in MYC-regulated TFRC expression in a MYC-driven prostate cancer xenograft model. Moreover, (89)Zr-transferrin imaging can detect the in situ development of prostate cancer in a transgenic MYC prostate cancer model, as well as in prostatic intraepithelial neoplasia (PIN) before histological or anatomic evidence of invasive cancer. These preclinical data establish (89)Zr-transferrin as a sensitive tool for noninvasive measurement of oncogene-driven TFRC expression in prostate and potentially other cancers, with prospective near-term clinical application.


Subject(s)
Positron-Emission Tomography/methods , Prostatic Intraepithelial Neoplasia/diagnostic imaging , Prostatic Neoplasms/diagnostic imaging , Proto-Oncogene Proteins c-myc/metabolism , Transferrin , Zirconium , Animals , Deferoxamine , Male , Mice , Mice, Transgenic , Radioisotopes , Radiopharmaceuticals , Receptors, Transferrin/metabolism , Transplantation, Heterologous
13.
Cancer Discov ; 2(4): 320-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22576209

ABSTRACT

UNLABELLED: Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clinical biomarker could more clearly assess the advantages of imaging cancer. The virtues and shortcomings of measuring secreted prostate-specific antigen (PSA), an androgen receptor (AR) target gene, in patients with prostate cancer are well documented, making it a logical candidate for assessing whether a radiotracer can reveal new (and useful) information beyond that conferred by serum PSA. Therefore, we developed (89)Zr-labeled 5A10, a novel radiotracer that targets "free" PSA. (89)Zr-5A10 localizes in an AR-dependent manner in vivo to models of castration-resistant prostate cancer, a disease state in which serum PSA may not reflect clinical outcomes. Finally, we demonstrate that (89)Zr-5A10 can detect osseous prostate cancer lesions, a context where bone scans fail to discriminate malignant and nonmalignant signals. SIGNIFICANCE: This report establishes that AR-dependent changes in PSA expression levels can be quantitatively measured at tumor lesions using a radiotracer that can be rapidly translated for human application and advances a new paradigm for radiotracer development that may more clearly highlight the unique virtues of an imaging biomarker.


Subject(s)
Molecular Imaging , Prostate-Specific Antigen/metabolism , Radioactive Tracers , Receptors, Androgen/metabolism , Signal Transduction , Animals , Cell Line, Tumor , Disease Models, Animal , Humans , Male , Mice , Molecular Imaging/methods , Orchiectomy , Positron-Emission Tomography , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/therapy , Radioisotopes/administration & dosage , Tomography, X-Ray Computed , Zirconium/administration & dosage
14.
Semin Nucl Med ; 41(4): 265-82, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21624561

ABSTRACT

Although (18)F-fluorodeoxyglucose ((18)F-FDG) is still the most widely used positron emission tomography (PET) radiotracer, there are a few well-known limitations to its use. The last decade has seen the development of new PET probes for in vivo visualization of specific molecular targets, along with important technical advances in the production of positron-emitting radionuclides and their related labeling methods. As such, a broad range of new PET tracers are in preclinical development or have recently entered clinical trials. The topics covered in this review include labeling methods, biological targets, and the most recent preclinical or clinical data of some of the next generation of PET radiopharmaceuticals. This review, which is by no means exhaustive, has been separated into sections related to the PET radionuclide used for radiolabeling: fluorine-18, for the labeling of agents such as FACBC, FDHT, choline, and Galacto-RGD; carbon-11, for the labeling of choline; gallium-68, for the labeling of peptides such as DOTATOC and bombesin analogs; and the long-lived radionuclides iodine-124 and zirconium-89 for the labeling of monoclonal antibodies cG250, and J591 and trastuzumab, respectively.


Subject(s)
Medical Oncology/methods , Positron-Emission Tomography/methods , Radioisotopes/chemistry , Radiopharmaceuticals/chemistry , Antibodies, Monoclonal/chemistry , Carbon Radioisotopes/chemistry , Fluorine Radioisotopes/chemistry , Gallium Radioisotopes/chemistry , Iodine Radioisotopes/chemistry , Isotope Labeling , Zirconium/chemistry
15.
BMC Med Genet ; 5: 14, 2004 Jun 02.
Article in English | MEDLINE | ID: mdl-15175114

ABSTRACT

BACKGROUND: The p73 protein, a paralogue of the p53 tumor suppressor, is essential for normal development and survival of neurons. TP73 is therefore of interest as a candidate gene for Alzheimer's disease (AD) susceptibility. TP73 mRNA is transcribed from three promoters, termed P1-P3, and there is evidence for an additional complexity in its regulation, namely, a variable allelic expression bias in some human tissues. METHODS: We utilized RT-PCR/RFLP and direct cDNA sequencing to measure allele-specific expression of TP73 mRNA, SNP genotyping to assess genetic associations with AD, and promoter-reporter assays to assess allele-specific TP73 promoter activity. RESULTS: Using a coding-neutral BanI polymorphism in TP73 exon 5 as an allelic marker, we found a pronounced allelic expression bias in one adult brain hippocampus, while 3 other brains (two adult; one fetal) showed approximately equal expression from both alleles. In a tri-ethnic elderly population of African-Americans, Caribbean Hispanics and Caucasians, a G/A single nucleotide polymorphism (SNP) at -386 in the TP73 P3 promoter was weakly but significantly associated with AD (crude O.R. for AD given any -386G allele 1.7; C.I. 1.2-2.5; after adjusting for age and education O.R. 1.5; C.I. 1.1-2.3, N= 1191). The frequency of the -386G allele varied by ethnicity and was highest in African-Americans and lowest in Caucasians. No significant differences in basal P3 promoter activity were detected comparing -386G vs. -386A promoter-luciferase constructs in human SK-NSH-N neuroblastoma cells. CONCLUSIONS: There is a reproducible allelic expression bias in mRNA expression from the TP73 gene in some, though not all, adult human brains, and inter-individual variation in regulatory sequences of the TP73 locus may affect susceptibility to AD. However, additional studies will be necessary to exclude genetic admixture as an alternative explanation for the observed associations.


Subject(s)
Alzheimer Disease/genetics , Brain/metabolism , DNA-Binding Proteins/genetics , Gene Expression/genetics , Nuclear Proteins/genetics , Aged , Alzheimer Disease/ethnology , Apolipoproteins E/genetics , Base Sequence , Brain/pathology , Cell Line, Tumor , DNA/genetics , DNA Mutational Analysis , DNA, Complementary/chemistry , DNA, Complementary/genetics , Gene Frequency , Genes, Tumor Suppressor , Genetic Predisposition to Disease/genetics , Genotype , Humans , Luciferases/genetics , Luciferases/metabolism , Odds Ratio , Polymorphism, Restriction Fragment Length , Polymorphism, Single Nucleotide/genetics , Promoter Regions, Genetic/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tumor Protein p73 , Tumor Suppressor Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...